These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 15920295)

  • 1. The use of proteomics in biomarker discovery in neurodegenerative diseases.
    Davidsson P; Sjögren M
    Dis Markers; 2005; 21(2):81-92. PubMed ID: 15920295
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between β-Secretase, inflammation and core cerebrospinal fluid biomarkers for Alzheimer's disease.
    Alcolea D; Carmona-Iragui M; Suárez-Calvet M; Sánchez-Saudinós MB; Sala I; Antón-Aguirre S; Blesa R; Clarimón J; Fortea J; Lleó A
    J Alzheimers Dis; 2014; 42(1):157-67. PubMed ID: 24820015
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer's disease core biomarkers in Lewy body disorders and Alzheimer's dementia.
    Chiasserini D; Biscetti L; Eusebi P; Salvadori N; Frattini G; Simoni S; De Roeck N; Tambasco N; Stoops E; Vanderstichele H; Engelborghs S; Mollenhauer B; Calabresi P; Parnetti L
    Alzheimers Res Ther; 2017 Jul; 9(1):52. PubMed ID: 28750675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proteomic analysis of cerebrospinal fluid in Alzheimer's disease: wanted dead or alive.
    Oláh Z; Kálmán J; Tóth ME; Zvara Á; Sántha M; Ivitz E; Janka Z; Pákáski M
    J Alzheimers Dis; 2015; 44(4):1303-12. PubMed ID: 25428253
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of novel CSF biomarkers for neurodegeneration and their validation by a high-throughput multiplexed targeted proteomic assay.
    Heywood WE; Galimberti D; Bliss E; Sirka E; Paterson RW; Magdalinou NK; Carecchio M; Reid E; Heslegrave A; Fenoglio C; Scarpini E; Schott JM; Fox NC; Hardy J; Bhatia K; Heales S; Sebire NJ; Zetterberg H; Mills K
    Mol Neurodegener; 2015 Dec; 10():64. PubMed ID: 26627638
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proteomic studies of cerebrospinal fluid biomarkers of Alzheimer's disease: an update.
    Portelius E; Brinkmalm G; Pannee J; Zetterberg H; Blennow K; Dahlén R; Brinkmalm A; Gobom J
    Expert Rev Proteomics; 2017 Nov; 14(11):1007-1020. PubMed ID: 28942688
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proteomics of human cerebrospinal fluid: discovery and verification of biomarker candidates in neurodegenerative diseases using quantitative proteomics.
    Kroksveen AC; Opsahl JA; Aye TT; Ulvik RJ; Berven FS
    J Proteomics; 2011 Apr; 74(4):371-88. PubMed ID: 21111852
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The cerebrospinal fluid levels of tau, growth-associated protein-43 and soluble amyloid precursor protein correlate in Alzheimer's disease, reflecting a common pathophysiological process.
    Sjögren M; Davidsson P; Gottfries J; Vanderstichele H; Edman A; Vanmechelen E; Wallin A; Blennow K
    Dement Geriatr Cogn Disord; 2001; 12(4):257-64. PubMed ID: 11351137
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic function of the neuroinflammatory biomarker YKL-40 in Alzheimer's disease and other neurodegenerative diseases.
    Baldacci F; Lista S; Cavedo E; Bonuccelli U; Hampel H
    Expert Rev Proteomics; 2017 Apr; 14(4):285-299. PubMed ID: 28281838
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of cerebrospinal fluid (CSF) beta-amyloid (1-42), phosphorylated tau (ptau-181) and total Tau protein in patients with Alzheimer's disease (AD) and other dementia at Siriraj Hospital, Thailand.
    Thaweepoksomboon J; Senanarong V; Poungvarin N; Chakorn T; Siwasariyanon N; Washirutmangkur L; Udompunthuruk S
    J Med Assoc Thai; 2011 Feb; 94 Suppl 1():S77-83. PubMed ID: 21721431
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A targeted proteomic multiplex CSF assay identifies increased malate dehydrogenase and other neurodegenerative biomarkers in individuals with Alzheimer's disease pathology.
    Paterson RW; Heywood WE; Heslegrave AJ; Magdalinou NK; Andreasson U; Sirka E; Bliss E; Slattery CF; Toombs J; Svensson J; Johansson P; Fox NC; Zetterberg H; Mills K; Schott JM
    Transl Psychiatry; 2016 Nov; 6(11):e952. PubMed ID: 27845782
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain.
    Tapiola T; Alafuzoff I; Herukka SK; Parkkinen L; Hartikainen P; Soininen H; Pirttilä T
    Arch Neurol; 2009 Mar; 66(3):382-9. PubMed ID: 19273758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amyloid β (Aβ) and phospho-tau (p-tau) as diagnostic biomarkers in Alzheimer's disease.
    Prvulovic D; Hampel H
    Clin Chem Lab Med; 2011 Mar; 49(3):367-74. PubMed ID: 21342022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma Proteomic Profiles of Cerebrospinal Fluid-Defined Alzheimer's Disease Pathology in Older Adults.
    Dayon L; Wojcik J; Núñez Galindo A; Corthésy J; Cominetti O; Oikonomidi A; Henry H; Migliavacca E; Bowman GL; Popp J
    J Alzheimers Dis; 2017; 60(4):1641-1652. PubMed ID: 29125490
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decreased CSF-beta-amyloid 42 in Alzheimer's disease and amyotrophic lateral sclerosis may reflect mismetabolism of beta-amyloid induced by disparate mechanisms.
    Sjögren M; Davidsson P; Wallin A; Granérus AK; Grundström E; Askmark H; Vanmechelen E; Blennow K
    Dement Geriatr Cogn Disord; 2002; 13(2):112-8. PubMed ID: 11844893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proteomic analysis of cerebrospinal fluid extracellular vesicles: a comprehensive dataset.
    Chiasserini D; van Weering JR; Piersma SR; Pham TV; Malekzadeh A; Teunissen CE; de Wit H; Jiménez CR
    J Proteomics; 2014 Jun; 106():191-204. PubMed ID: 24769233
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.
    Lautner R; Palmqvist S; Mattsson N; Andreasson U; Wallin A; Pålsson E; Jakobsson J; Herukka SK; Owenius R; Olsson B; Hampel H; Rujescu D; Ewers M; Landén M; Minthon L; Blennow K; Zetterberg H; Hansson O;
    JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CSF amyloid-beta and tau proteins, and cognitive performance, in early and untreated Parkinson's disease: the Norwegian ParkWest study.
    Alves G; Brønnick K; Aarsland D; Blennow K; Zetterberg H; Ballard C; Kurz MW; Andreasson U; Tysnes OB; Larsen JP; Mulugeta E
    J Neurol Neurosurg Psychiatry; 2010 Oct; 81(10):1080-6. PubMed ID: 20547614
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study.
    Li QX; Villemagne VL; Doecke JD; Rembach A; Sarros S; Varghese S; McGlade A; Laughton KM; Pertile KK; Fowler CJ; Rumble RL; Trounson BO; Taddei K; Rainey-Smith SR; Laws SM; Robertson JS; Evered LA; Silbert B; Ellis KA; Rowe CC; Macaulay SL; Darby D; Martins RN; Ames D; Masters CL; Collins S;
    J Alzheimers Dis; 2015; 48(1):175-87. PubMed ID: 26401938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How many biomarkers to discriminate neurodegenerative dementia?
    Sancesario GM; Bernardini S
    Crit Rev Clin Lab Sci; 2015; 52(6):314-26. PubMed ID: 26292074
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.